Viveve Medical (VIVE) and Newcardio (NWCI) Head to Head Survey

Viveve Medical (NASDAQ:VIVE) and Newcardio (OTCMKTS:NWCI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.


This table compares Viveve Medical and Newcardio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viveve Medical -243.98% -838.28% -104.99%
Newcardio N/A N/A N/A

Institutional and Insider Ownership

52.1% of Viveve Medical shares are held by institutional investors. 35.1% of Viveve Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Viveve Medical and Newcardio’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viveve Medical $15.29 million 2.85 -$36.95 million ($2.11) -0.65
Newcardio N/A N/A N/A N/A N/A

Newcardio has lower revenue, but higher earnings than Viveve Medical.

Risk and Volatility

Viveve Medical has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Comparatively, Newcardio has a beta of 6.83, suggesting that its share price is 583% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Viveve Medical and Newcardio, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viveve Medical 0 1 5 0 2.83
Newcardio 0 0 0 0 N/A

Viveve Medical presently has a consensus target price of $8.75, suggesting a potential upside of 534.06%. Given Viveve Medical’s higher probable upside, research analysts plainly believe Viveve Medical is more favorable than Newcardio.


Viveve Medical beats Newcardio on 5 of the 9 factors compared between the two stocks.

Viveve Medical Company Profile

Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Newcardio Company Profile

NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with's FREE daily email newsletter.

Leave a Reply